FDA Opens Dialogue on Possible Benefits, Harms From Use of AI/ML in Drug Development

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

FDA Opens Dialogue on Possible Benefits, Harms From Use of AI/ML in Drug Development

J.W. Schomisch

May 14, 2023 at 07:15 PM EST

Although the use of artificial intelligence and machine learning (AI/ML) has the potential to make clinical trials safer and more efficient, the technologies also have the potential to introduce risks and harms. The FDA on May 10 initiated what the agency hopes is an ongoing dialogue with industry and academia on the use of the technologies across the drug development process... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Opens Dialogue on Possible Benefits, Harms From Use of AI/ML in Drug Development

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT